Clinical trial
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
NCT07398937
Study timeline
Study start (estimated)2026-02-05Date precision: day
Registry last updated2026-02-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Resectable Stage II-IIIa Squamous NSCLCunresolved
Interventions
Sponsors & collaborators
Fudan Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07398937 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.